Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level685 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,087 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06787170 | Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer(PPRPHGSOC) | completed | — | 1,129 | The First People's Hospital of YunnanOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06789224 | Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device(REMOVE) | completed | N/A | 136 | Lindis Bloodcare GmbHINDUSTRY |
| 1 |
| Jan 23, 2025 |
| clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT05904730 | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations | completed | Phase 1 | 10 | Lynkcell EuropeOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00170573 | Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 77 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT03752216 | NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.(NiQoLe) | completed | Phase 4 | 141 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT02054351 | Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)(OVAR) | completed | Phase 1 | 42 | Ganymed Pharmaceuticals GmbHINDUSTRY | 2 | Nov 21, 2024 | clinicaltrials |
| NCT03159572 | Homologous Recombination Inquiry Through Ovarian Malignancy Investigations(HITOMI) | completed | — | 996 | Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT06697613 | Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian Cancer | completed | — | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients(MAMOC) | completed | Phase 3 | 42 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04525183 | REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue | completed | N/A | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT00170625 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04458168 | Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living | completed | N/A | 120 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT03378297 | IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC(IMPACT) | completed | Early Phase 1 | 26 | Haukeland University HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT03246074 | Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer | completed | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT05427214 | Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy(Dragon) | completed | N/A | 52 | Washington University School of MedicineOTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT03596281 | Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer(PEMBOV) | completed | Phase 1 | 47 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06629831 | Systemic Inflammatory Biomarkers in Ovarian Cancer | completed | — | 90 | Bakirkoy Dr. Sadi Konuk Research and Training HospitalOTHER_GOV | 1 | Oct 9, 2024 | clinicaltrials |
| NCT03635489 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04927013 | Connecting Families to Overcome Ovarian Cancer | completed | N/A | 2,331 | Emory UniversityOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02480374 | Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer | completed | Phase 1 | 18 | ImunonINDUSTRY | 1 | Oct 2, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT05775549 | A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer(FLAME) | completed | — | 24 | AstraZenecaINDUSTRY | 1 | Sep 20, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT05344950 | Connecting Audio and Radio Sensing Systems to Improve Care at Home(AURA) | completed | — | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06599749 | Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn) | completed | — | 80 | University Hospital, Basel, SwitzerlandOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer(ANITA) | completed | Phase 3 | 417 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 5 | Aug 30, 2024 | clinicaltrials |
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer(SGI-110) | completed | Phase 2 | 120 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT01606241 | Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 24 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT04067960 | Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer | completed | Early Phase 1 | 197 | Mayo ClinicOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03539406 | Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients(INTRO) | completed | Phase 1 | 11 | Radboud University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05132868 | Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling | completed | N/A | 78 | Stanford UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03133286 | Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)(RADIANT) | completed | — | 16 | DxTerity DiagnosticsINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03206177 | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | completed | Phase 1 | 26 | University of OklahomaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04296890 | A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression(SORAYA) | completed | Phase 3 | 106 | ImmunoGen, Inc.INDUSTRY | 11 | Aug 7, 2024 | clinicaltrials |
| NCT03154281 | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | completed | Phase 1 | 14 | Avera McKennan Hospital & University Health CenterOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2025source: clinicaltrials